$40.52
37.69% today
Nasdaq, Feb 28, 04:50 pm CET
ISIN
US74006W1080
Symbol
PRAX
Sector
Industry

Praxis Precision Medicines Inc Stock price

$65.03
-8.27 11.28% 1M
+11.51 21.51% 6M
-11.93 15.50% YTD
+16.19 33.15% 1Y
-131.47 66.91% 3Y
-219.97 77.18% 5Y
-219.97 77.18% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-3.36 4.91%
ISIN
US74006W1080
Symbol
PRAX
Sector
Industry

Key metrics

Market capitalization $1.21b
Enterprise Value $856.65m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 532.08
P/S ratio (TTM) P/S ratio 752.81
P/B ratio (TTM) P/B ratio 3.02
Revenue growth (TTM) Revenue growth -16.93%
Revenue (TTM) Revenue $1.61m
EBIT (operating result TTM) EBIT $-164.02m
Free Cash Flow (TTM) Free Cash Flow $-98.45m
Cash position $357.03m
EPS (TTM) EPS $-10.30
P/E forward negative
P/S forward 828.36
EV/Sales forward 585.48
Short interest 14.09%
Show more

Is Praxis Precision Medicines Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Praxis Precision Medicines Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Praxis Precision Medicines Inc forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Praxis Precision Medicines Inc forecast:

Buy
91%
Hold
9%

Financial data from Praxis Precision Medicines Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1.61 1.61
17% 17%
100%
- Direct Costs 0.42 0.42
66% 66%
26%
1.18 1.18
71% 71%
73%
- Selling and Administrative Expenses 50 50
18% 18%
3,122%
- Research and Development Expense 115 115
18% 18%
7,112%
-164 -164
18% 18%
-10,161%
- Depreciation and Amortization 0.42 0.42
66% 66%
26%
EBIT (Operating Income) EBIT -164 -164
17% 17%
-10,187%
Net Profit -151 -151
10% 10%
-9,380%

In millions USD.

Don't miss a Thing! We will send you all news about Praxis Precision Medicines Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Praxis Precision Medicines Inc Stock News

Neutral
GlobeNewsWire
about 3 hours ago
BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided an update on the interim analysis for Study 1 of the Essential3 program of ulixacal...
Neutral
GlobeNewsWire
24 days ago
BOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on February 3, 2025, the Compensation Committee of Praxis' Board of Directors...
Neutral
GlobeNewsWire
25 days ago
BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences:
More Praxis Precision Medicines Inc News

Company Profile

Praxis Precision Medicines, Inc. is a clinical-stage genetic neuroscience company that develops therapies for patients and families affected by complex and debilitating brain disorders. The company was founded by Kiran Reddy, David Goldstein and Steven Petrou on September 22, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Marcio Souza
Employees 82
Founded 2015
Website www.praxismedicines.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today